Twin Tree Management
ALXN

Twin Tree Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Twin Tree Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,700
Closed -$1.98M – 1698
2020
Q4 		$1.98M Sell
12,700
-1,500
-11% -$193K 0.01% 856
2020
Q3 		$1.63M Sell
14,200
-145,900
-91% -$15.7M 0.01% 801
2020
Q2 		$18M Sell
160,100
-121,500
-43% -$12.9M 0.07% 298
2020
Q1 		$25.3M Buy
281,600
+256,000
+1,000% +$25.1M 0.12% 152
2019
Q4 		$2.77M Buy
25,600
+24,700
+2,744% +$2.64M 0.01% 644
2019
Q3 		$88K Buy
+900
New +$101K ﹤0.01% 1014
2019
Q2 		– Sell
-152,400
Closed -$20.6M – 1657
2019
Q1 		$20.6M Sell
152,400
-8,100
-5% -$1.01M 0.11% 172
2018
Q4 		$15.6M Buy
160,500
+153,900
+2,332% +$18.2M 0.1% 221
2018
Q3 		$917K Sell
6,600
-9,600
-59% -$1.2M 0.01% 739
2018
Q2 		$2.01M Buy
16,200
+12,000
+286% +$1.4M 0.01% 634
2018
Q1 		$468K Sell
4,200
-73,200
-95% -$8.75M ﹤0.01% 803
2017
Q4 		$9.26M Sell
77,400
-53,500
-41% -$6.52M 0.07% 255
2017
Q3 		$18.4M Buy
130,900
+116,700
+822% +$15.9M 0.15% 143
2017
Q2 		$1.73M Buy
+14,200
New +$1.65M 0.01% 580
2017
Q1 		– Sell
-32,200
Closed -$3.94M – 1340
2016
Q4 		$3.94M Buy
32,200
+28,000
+667% +$3.43M 0.04% 451
2016
Q3 		$515K Sell
4,200
-20,200
-83% -$2.6M 0.01% 824
2016
Q2 		$2.85M Buy
+24,400
New +$3.46M 0.04% 389
2016
Q1 		– Sell
-9,100
Closed -$1.74M – 1564
2015
Q4 		$1.74M Buy
9,100
+2,500
+38% +$437K 0.03% 457
2015
Q3 		$1.03M Sell
6,600
-41,100
-86% -$7.5M 0.03% 531
2015
Q2 		$8.62M Buy
47,700
+31,600
+196% +$5.45M 0.21% 93
2015
Q1 		$2.79M Sell
16,100
-7,400
-31% -$1.34M 0.07% 298
2014
Q4 		$4.35M Buy
23,500
+9,500
+68% +$1.76M 0.12% 176
2014
Q3 		$2.32M Sell
14,000
-6,100
-30% -$1M 0.06% 337
2014
Q2 		$3.14M Buy
20,100
+16,000
+390% +$2.53M 0.07% 296
2014
Q1 		$624K Sell
4,100
-7,000
-63% -$1.11M 0.01% 723
2013
Q4 		$1.48M Buy
+11,100
New +$1.33M 0.04% 498

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Tree Management's ALXN Position: Q1 2021 in Review

Twin Tree Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 36,182 shares — an estimated $5.65M sold.

Twin Tree Management first reported a position in ALXN in Q4 2013 and held it in 20 quarters. The position peaked at $15.2M in Q1 2020. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Twin Tree Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Twin Tree Management sold 36,182 Alexion Pharmaceuticals shares in Q1 2021, an estimated $5.65M.
  • Twin Tree Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 20 quarters.
  • Twin Tree Management's Alexion Pharmaceuticals position peaked at $15.2M in Q1 2020.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Twin Tree Management's 13F filing for Q1 2021, filed 17 May 2021.